Resource utilisation in the management of dyslipidaemia

PharmacoEconomics

Volumn 14, Issue SUPPL. 3, 1998, Pages 11-18

  Szucs, Thomas D ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; CORONARY RISK; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DYSLIPIDEMIA; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; REVIEW;

EID: 0032419164     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814003-00002     Document Type: Review

References (57)

1. American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas: American Heart Association, 1997
2. Reckless JPD. Cost-effectiveness of hypolipidaemic drugs. Postgrad Med J 1993; 69 Suppl. 1: S30-3
3. Johannesson M, Borgquist L, Nilsson-Ehle P, et al. The cost of screening for hypercholesterolemia - results from a clinical trial in Swedish primary health care. Scand J Clin Lab Invest 1993; 53: 725-32
4. Simvastatin cost-effective in secondary prevention. Scrip Mag 1995; 2013: 30
5. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124 Suppl: S1-9
6. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-445
7. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84
8. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-7
9. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-36
10. Miller M, Seidler A, Moalemi A, et al. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998; 31: 1252-7
11. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology. European Atherosclerosis Society and the European Society of Hypertension. Eur Heart J 1994; 15: 1300-31
12. Office of Population Censuses and Surveys (OPCS). Mortality statistics: cause, series DH2 no. 19, 1992. London: HMSO, 1993
13. Ruckdäschel S, Berger K, Szucs TD. Die koronare Herzkrankheit-ein soziookonomische Problem? Munch Med Wochenschr 1996; 138: 404-8
14. Sagmeister M, Gessner U, Oggier W, et al. An economic analysts of ischemic heart disease in Switzerland. Eur Heart J 1997; 18: 1102-9
15. Currie CJ, Morgan CL, Peters JR. Patterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart 1997; 78: 544-9
16. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998; 81: 110-5
17. Anderson KM, Wilson PWF, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83: 356-62
18. D'Agostino RB, Russell MW, Huse DM, et al. Primary and secondary coronary risk appraisal: new results from the Framingham Study. J Am Coll Cardiol. In Press
19. Office of Health Economics. Coronary heart disease. The need for action. Statement from the Office of Health Economics, London: 1990, 15-18
20. Kuntz, KM, Lee TH. Cost-effectiveness of accepted measures for intervention in coronary heart disease. Coron Artery Dis 1995; 6: 472-8
21. Scott WG, White HD, Scott HM. Cost of coronary heart disease in New Zealand. NZ Med J 1993; 106: 347-9
22. Mann JI, Lewis B, Shepherd J, et al. Blood lipid concentrations and other cardiovascular risk factors: distrihtition, prevalence and detection in Britain. BMJ 1988; 296: 1702-6
23. Gordon T, Kannel WB, Castelli WP, et al. Lipoproteins, cardiovascular disease, and death: the Framingham study. Arch Intern Med 1981; 141: 1128-31
24. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986; 256: 2835-8
25. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8
26. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176-80
27. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316 099 white men. Arch Intern Med 1992; 152: 56-64
28. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997; 79: 756-62
29. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
30. Frick MH, Elo MO, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
31. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
32. Sacks FM, Pfeifer MA, Move LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
33. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
34. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81
35. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55
36. Simes RJ, Baker S, MacMahon S, et al. Pravastatin reduces total mortality in patients with coronary heart disease and average cholesterol levels: relationship of baseline cholesterol and treatment effects in the LIPID trial. Presented at the 47th Annual Scientific Session of the American College of Cardiology: 1998 Mar 29-Apr 1; Atlanta, Georgia: USA
37. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
38. Gould AL, Rossouu JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-52
39. Holme I. Effects of lipid-lowering therapy on total and coronary mortality. Curr Opin Lipidol 1995; 6(6): 374-8
40. Berwick DM, Cretin S, Keeler B. Cholesterol, children and heart disease: an analysis of alternatives. Pediatrics 1981; 68: 721-30
41. Kristiansen IS, Eggen AE, Thelle DS. Cost-effectiveness of incremental programmes for lowering cholesterol concentration: is individual intervention worthwhile? BMJ 1991; 302: 1119-22
42. Kinlay S, O'Connell D, Evans D, et al. The cost-effectiveness of difterent blood-cholesterol-lowering strategies in the prevention of coronary heart disease. Aust J Public Health 1994; 18: 105-10
43. Hall JP, Heller RF, Dobson AJ, et al. A cost-effectiveness analysis of alternative strategies for the prevention of heart disease. Med J Aust 1988; 148: 273-7
44. Reckless JPD. Cost effectiveness of clinical care for hyperlipidaemia. In: Lewis B, Assmann G, editors. The social and economic contexts of coronary prevention. London: Current Medical Literature, 1990: 94-103
45. Smith WCS, Kenicer MB, Maryon Davis A, et al. Blood cholesterol: is population screening warranted in the UK? Lancet 1989; 1: 372-3
46. O'Brien BJ. Cholesterol and coronary heart disease: consensus or controversy? 8. Questions of cost-effectiveness. London: Office of Health Economics, 1991: 78-100
47. Grover SA, Coupal L, Fahkry R, et al. Screening for hypercholesterolemia among Canadians: how much will it cost? Can Med Assoc J 1991; 144: 161-8
48. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129-33
49. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression study (STARS). Lancet 1992; 339: 563-9
50. Ramsey LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. BMJ 1991; 303: 953-7
51. Reckless JPD. The 4S study and its pharmacoeconomic implications. Pharmacoeconomics 1996; 9: 101-5
52. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145-51
53. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 95: 1796-802
54. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
55. Schwartz JS, Boccuzzi SJ, Murray JF, et al. Cost effectiveness of LDL-C reduction in Medicare managed care CHD patients: implications from the Scandinavian Simvastatin Survival Study (4S) [abstract no. 767-2]. J Am Coll Cardiol 1997; 29 Suppl. A: 226
56. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-42
57. Morris S, McGuire A, Caro J, et al. Strategies for the management of hypercholesterolemia: a systematic review of the cost-effectiveness literature. J Health Serv Res Policy 1997; 2: 231-50